- Home
- BIOA vs ACRS Comparison
BIOA vs ACRS Comparison
Compare BIOA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- ACRS
- Stock Information
- Founded
- BIOA 2015
- ACRS 2012
- Country
- BIOA United States
- ACRS United States
- Employees
- BIOA N/A
- ACRS N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- BIOA Health Care
- ACRS Health Care
- Exchange
- BIOA Nasdaq
- ACRS Nasdaq
- Market Cap
- BIOA 175.7M
- ACRS 198.2M
- IPO Year
- BIOA 2024
- ACRS 2015
- Fundamental
- Price
- BIOA $5.45
- ACRS $1.92
- Analyst Decision
- BIOA Hold
- ACRS Strong Buy
- Analyst Count
- BIOA 4
- ACRS 9
- Target Price
- BIOA $5.67
- ACRS $9.25
- AVG Volume (30 Days)
- BIOA 189.4K
- ACRS 1.0M
- Earning Date
- BIOA 11-06-2025
- ACRS 11-05-2025
- Dividend Yield
- BIOA N/A
- ACRS N/A
- EPS Growth
- BIOA N/A
- ACRS N/A
- EPS
- BIOA N/A
- ACRS N/A
- Revenue
- BIOA $3,863,000.00
- ACRS $16,789,000.00
- Revenue This Year
- BIOA N/A
- ACRS N/A
- Revenue Next Year
- BIOA N/A
- ACRS $7.02
- P/E Ratio
- BIOA N/A
- ACRS N/A
- Revenue Growth
- BIOA N/A
- ACRS N/A
- 52 Week Low
- BIOA $2.88
- ACRS $1.05
- 52 Week High
- BIOA $26.62
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- BIOA 63.40
- ACRS 52.48
- Support Level
- BIOA $4.88
- ACRS $1.84
- Resistance Level
- BIOA $5.34
- ACRS $1.99
- Average True Range (ATR)
- BIOA 0.26
- ACRS 0.12
- MACD
- BIOA 0.04
- ACRS -0.01
- Stochastic Oscillator
- BIOA 95.06
- ACRS 34.33
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.